The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
RTOG 0913: A phase I study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Prakash Chinnaiyan
Research Funding - Merck
Minhee Won
No relevant relationships to disclose
Patrick Y. Wen
Honoraria - Merck
Research Funding - Merck
Amyn Rojiani
No relevant relationships to disclose
Merideth M Wendland
No relevant relationships to disclose
Thomas A. DiPetrillo
No relevant relationships to disclose
Benjamin W. Corn
No relevant relationships to disclose
Minesh P. Mehta
Consultant or Advisory Role - Merck; Roche
Honoraria - Merck